2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - 243-245
Technology and Procedures, Gene Editing, Treatment Considerations, Drug Development, Biological Processes, Hematopoiesis, Molecular Biology, Diseases, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Metabolic Disorders, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Pediatric
PAPER

9 Long-term changes in iron overload and markers of iron regulation and erythropoiesis with mitapivat in patients with α– or β–non–transfusion-dependent thalassemia: Results from the phase 3 ENERGIZE open-label extension

Hanny Al-Samkari, MD, Khaled M Musallam, MD, PhD2, Keely Gilroy, PhD3, Leonardo Rivadeneyra, PhD4, Lauren Czapla, APN5, Jing Zhao, PhD6, Ali Taher, MD, PhD7, Kevin HM Kuo, MD, MSc, FRCPC8
1 Harvard Medical School, Boston, Massachusetts, United States
2 Burjeel Medical City, Abu Dhabi, United Arab Emirates, Khalifa University, Abu Dhabi, United Arab Emirates, Weill Cornell Medicine, New York, New York, United States
3 Agios Pharmaceuticals, Cambridge, Massachusetts, United States
4 Agios Pharmaceuticals, Cambridge, Massachusetts, United States
5 Agios Pharmaceuticals, Cambridge, Massachusetts, United States
6 Agios Pharmaceuticals, Cambridge, Massachusetts, United States
7 American University of Beirut Medical Center, Beirut, Lebanon
8 University of Toronto, Toronto, Ontario, Canada

Introduction

Non–transfusion-dependent thalassemia (NTDT) is characterized by chronic anemia and progressive iron overload, which contribute to long-term organ morbidity even in the absence of regular transfusions. Anemia severity has been shown to correlate with the magnitude of iron overload in NTDT, suggesting that treatments targeting the underlying pathophysiology of thalassemia may reduce long‑term iron accumulation and associated morbidity. Mitapivat, a first‑in‑class oral allosteric activator of both the red blood cell–specific PKR isoform and the PKM2 isoform of pyruvate kinase, improves red blood cell metabolism and targets the underlying pathophysiology of ineffective erythropoiesis and hemolytic anemia. In the phase 3 ENERGIZE trial in α‑ or β‑NTDT (NCT04770753), mitapivat led to clinically meaningful increases in hemoglobin and improvements in patient-reported fatigue and markers of hemolysis. We evaluated the impact of long-term mitapivat treatment on iron overload and markers of iron regulation and erythropoiesis in patients with NTDT in the ENERGIZE open-label extension (OLE).

Methods

This analysis included patients randomized to mitapivat who continued treatment in the OLE. Liver iron concentration (LIC; per magnetic resonance imaging, mg/g), serum ferritin (µg/L), erythroferrone (ERFE; ng/L), soluble transferrin receptor (sTfR; nmol/L), and hepcidin (ng/L) were reported as mean (standard deviation [SD]) at screening (baseline) and mean change from baseline through week 144 after randomization. A subgroup analysis of LIC and ferritin by baseline LIC (<5 vs ≥5 mg/g) was also performed.

Results

ENERGIZE patient demographics were previously reported. Among patients who received ≥1 dose of mitapivat in the double-blind period (n=129), 121 continued receiving mitapivat in the OLE and were included in these analyses. Baseline mean (SD) LIC was 5.51 (5.10) mg/g (n=93) and decreased over time, with a mean (SD) change from baseline of –0.85 (1.97) mg/g at Week 48 (n=86), –0.72 (2.69) mg/g at Week 96 (n=80), and –0.90 (4.91) mg/g at Week 144 (n=39). Baseline mean (SD) ferritin was 658.27 (571.35) µg/L (n=120) and also declined over time, with a mean (SD) change from baseline of –66.21 (270.94) µg/L at Week 48 (n=114), –62.09 (308.02) µg/L at Week 72 (n=109), –84.22 (378.87) µg/L at Week 96 (n=106), –90.70 (366.19) µg/L at Week 120 (n=101), and –118.82 (440.46) µg/L at Week 144 (n=46).

When patients were stratified by baseline LIC, those with baseline LIC ≥5 mg/g (n=36) showed consistent reductions in LIC (baseline mean [SD]: 10.20 [5.40] mg/g [n=36]; mean [SD] change from baseline: Week 48, –1.65 [2.95] mg/g [n=33]; Week 96, –1.53 [3.98] mg/g [n=33]; Week 144, –2.32 [6.48] mg/g [n=19]), whereas LIC remained stable in those with baseline LIC <5 mg/g (n=57). Trends in ferritin levels were consistent with LIC findings, with larger reductions in patients with baseline LIC ≥5 mg/g.

Changes in biomarkers of iron regulation supported a biological effect of mitapivat on improving erythropoiesis and iron regulation. Mean (SD) ERFE was 10,271.61 (8127.55) ng/L at baseline (n=121) and progressively decreased (mean [SD] change from baseline: Week 48, –1876.73 [3714.40] ng/L [n=112]; Week 120, –2260.10 [3637.14] ng/L [n=99]; Week 144, –2993.75 [4307.20] ng/L [n=45]). Mean (SD) sTfR was 224.00 (111.31) nmol/L at baseline (n=117) and decreased (mean [SD] change from baseline: Week 48, –19.80 [54.06] nmol/L [n=108]; Week 120, –32.32 [64.97] nmol/L [n=95]; Week 144, –32.26 [73.14] nmol/L [n=40]), consistent with improved erythropoiesis. Mean (SD) hepcidin was 22,936.73 (25,180.48) ng/L at baseline (n=120) and generally declined (mean [SD] change from baseline: Week 48, –3942.88 [21,025.91] ng/L [n=113]; Week 120, –6473.66 [16,433.08] ng/L [n=100]; Week 144, –4546.67 [15,326.46] ng/L [n=45]).

Conclusions

Sustained reductions in LIC and ferritin were observed through Week 144 in patients with NTDT receiving long-term mitapivat treatment, with greater reductions in those with higher baseline LIC. Improvements in LIC were accompanied by a decrease in hepcidin levels, consistent with changes in iron balance. Concomitant reductions in ERFE and sTfR were observed, supporting a mitigating effect of mitapivat on ineffective erythropoiesis, a key driver of iron overload in NTDT. By targeting this underlying pathophysiology, mitapivat may reduce iron loading and support a more physiologic iron handling through enhanced erythropoietic efficiency.

Hanny Al-Samkari, MD: Atavistik - Research Funding; Sanofi - Research Funding; Amgen - Research Funding; SOBI - Research Funding; Novartis - Research Funding; Alnylam - Research Funding; Vaderis - Research Funding; Tectonic - Research Funding; Argenx - Research Funding; Agios Pharmaceuticals - Research Funding; Alpine Immune Sciences - Research Funding; Pharmacosmos - Research Funding; Novartis - Consultancy (Includes expert testimony); Agios Pharmaceuticals - Consultancy (Includes expert testimony); Alnylam - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Argenx - Consultancy (Includes expert testimony); SOBI - Consultancy (Includes expert testimony); Tectonic - Consultancy (Includes expert testimony); Alpine Immune Sciences - Consultancy (Includes expert testimony); Diagonal - Consultancy (Includes expert testimony); Terremoto - Consultancy (Includes expert testimony); Pharmacosmos - Consultancy (Includes expert testimony); Atavistik - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony)